We have previously shown that topical brain application of kallikrein, an enzyme which converts kininogen to bradykinin, induces rabbit pial arteriole dilation. The purpose of the present investigation was to utilize a newly developed competitive kinin receptor antagonist to test the hypothesis that kallikrein-induced dilation was due to the conversion of brain kininogen to vasoactive kinins. As in our previous study, we measured rabbit pial arteriole diameter with a microscope using the closed cranial window technique. The kinin antagonist (6 /xM) reduced the dose-dependent dilation produced by bradykinin and blocked the dilation induced by kallikrein. In addition, the kinin antagonist was specific since it did not alter the cerebral arteriole dilation produced by adenosine, acetylcholine, or vasoactive intestinal polypeptide. These experiments provide further evidence for a possible role of the endogenous brain kallikrein-kinin system in the modulation of the cerebral circulation and provide the necessary pharmacologic foundation for future use of this antagonist in testing the role of kinins in the normal or altered cerebral circulation. (Stroke 1987; 18:792-795) W e and others have reported that bradykinin (BK) induces in vivo cerebral arteriole dilation. 1 " 4 We have recently shown that when kallikrein, the enzyme that converts kininogen to BK, is applied to the cerebral cortex, pial arteriole dilation is induced.
W e and others have reported that bradykinin
(BK) induces in vivo cerebral arteriole dilation. 1 " 4 We have recently shown that when kallikrein, the enzyme that converts kininogen to BK, is applied to the cerebral cortex, pial arteriole dilation is induced. 1 Proof that kallikrein indeed formed BK and that the BK induced dilation was derived from the following results. First, BK-or kallikrein-induced dilation were both prevented by topical coapplication of the cyclooxygenase inhibitors indomethacin or meclofenamic acid, implying that both substances induced dilation by a cyclooxygenasedependent mechanism. This cyclooxygenase dependency is in agreement with previous literature since it is well known that BK stimulates prostaglandin formation. 5 - 6 Secondly, the dilation induced by kallikrein was prevented by cotreatment with the kallikrein enzyme inhibitor aprotinin, implying that kallikreininduced dilation is due to its enzyme activity and not to a nonspecific effect. However, in spite of this evidence that kallikrein-induced dilation is due to BK formation it might still be argued that kallikrein-induced dilation is due to the formation of some cyclooxygenase-stimulating agonist other than a kinin.
Recently, Vavrek and Stewart 7 have synthesized and tested a competitive BK antagonist that blocks the action of exogenous BK, kallidin, and met-lys-brady-kinin in the guinea pig ileum, rat uterus, and rat blood pressure assays for kinins. They reported that this antagonist is specific since it does not affect the response of these organs to Angiotensin II or Substance P. However, the efficacy of this antagonist in blocking kinins generated from endogenous kininogens has not been examined. Also, the ability of the antagonist to block kinin action on the cerebral circulation has not been tested. To further determine whether the response to kallikrein is due to the formation of BK and to examine the efficacy of this compound as a tool in probing the role of kinins in the cerebral circulation, we have determined the effect of this newly described antagonist on BK-and kallikrein-induced cerebral arteriole dilation. Our current results provide further evidence that the cerebral circulation may be affected by BK formed from endogenous brain kininogen and provide evidence of the utility of a kinin receptor blocker for further studies of kinins and the cerebral circulation.
Materials and Methods
A total of 48 male New Zealand white rabbits weighing 3.3-4.2 kg were studied under anesthesia produced by 25 mg/kg i.v. sodium pentobarbital, 560 mg/kg subcutaneous urethane, and 38 mg/kg subcutaneous a-chloralose as previously reported.
1 Supplemental doses of pentobarbital were given as needed to maintain anesthesia. Under this regimen, surgical anesthesia was quickly induced with minimum respiratory depression, and the need for additional doses of pentobarbital was reduced.
After completion of a tracheotomy, each rabbit was ventilated with room air. The end-expiratory CO : of each rabbit was continuously monitored with an Anarad Inc. infrared CO 2 analyzer (Santa Barbara, Calif.) and was maintained at approximately 30 mm Hg throughout each experiment by adjusting the respirato-
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Rrg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-flrg BK R n t a g o n f s t flrg-Pro-Pro-Gly-Thi-Ser-DPhe-Thf-Rrg FIGURE 1. ry rate and volume. Arterial blood pressure was measured with a Statham P23Db pressure transducer connected to a cannula inserted into the left femoral artery. Arterial blood samples were periodically analyzed with an Instrumentation Laboratory blood pH-blood gas analyzer to ensure a normal range of Pao 2 , Paco 2 , and blood pH. Pial arterioles ranging between 29 and 100 fxm in diameter were examined using the previously described cranial window technique. 8 The 10-mm diam. cranial window was implanted on the midline just caudal to the suture connecting the frontal and parietal bones. The dura over the sagittal sinus was left in place; however, removal of the dura on each side of the sinus allowed visualization of arterioles on both cerebral hemispheres. Two to 4 vessels were studied in each rabbit using a Vickers image-splitting device (Woburn, Mass.) according to the method described by Baez. 9 The cranial window was equipped with 3 openings; 2 were used as inlet and outlet for filling the space under the cranial window with test solutions, and the third was connected to a Statham pressure transducer for continuous measurement of intracranial pres- sure (ICP). The ICP outlet of the window was connected to plastic tubing, the open end of which was placed at a fixed level to give a constant ICP of 5 mm Hg throughout the experiment. The space under the window and the plastic tubing connected to it were filled with artificial cerebrospinal fluid (CSF) 8 equilibrated with gas containing 6.6% oxygen, 5.9% carbon dioxide, and 87.5% nitrogen, which gives gas tensions and a pH in the normal range for CSF. The experiments were conducted using groups of 3-7 rabbits.
Bradykinin triacetate, kallikrein (from porcine pancreas), acetylcholine, adenosine, and indomethacin were purchased from Sigma Chemical Co. (St. Louis, Mo.), and vasoactive intestinal polypeptide (VIP) and Substance P were obtained from Peninsula Laboratories (Belmont, Calif.). All reagents were directly dissolved in CSF. Adenosine and acetylcholine stock solutions were prepared daily, as were kallikrein and indomethacin. As previously reported, 1 kallikrein (11 kallikrein units [KU]/mg solid) was dissolved in distilled water to produce a stock solution of 10 KU/ml that was added to artificial CSF to produce a final concentration of 1, 0.3, or 0.1 KU/ml CSF. All agents were applied topically; 1 ml of artificial CSF containing the agent or agents to be examined was perfused through the inlet and outlet ports over a period of approximately 1 minute. Arteriole diameter was then measured 2 and 5 minutes after completion of drug application.
The data describing the dose response to BK in the presence or absence of the BK antagonist were analyzed by repeated-measures analysis of variance (ANOVA) followed by examination of the group x dose interaction effect. The effect of the BK antagonist on kallikrein-induced dilation was evaluated by ANOVA and Tukey's Studentized range test. A p value ^0 . 0 5 was considered to be statistically significant.
Results and Discussion
The mean arterial blood pressure in all rabbits was 88 ± 1 mm Hg (mean ± SEM) and therefore was similar to that reported for unanesthetized rabbits.
l0 Arterial blood gases and pH were Pao 2 , 91 ± 1 mm Hg; Pacoj, 30 ± 1 mm Hg; and pH, 7.49 ± 0.01. Topical application of the various agents to the pial arterioles had no effect on systemic arterial blood pressure, blood gases, or pH. Figure 1 compares the amino acid composition of BK and the BK antagonist. Figure 2 shows that 6 fiM BK antagonist alone induced a slight but significant Stroke Vol 18, No 4, July-August 1987 (p<0.05) pial arteriole dilation. The antagonist blocked the effect of 8 x 10" 7 M BK and reduced the response to 8 x 10" 6 M BK by 40%. ANOVA was performed followed by examination of the group x dose interaction; the interaction was different at p<0.02. The dose-response curves of BK only and BK plus antagonist were different, indicating that the antagonist significantly reduced the response to BK. Limited availability of antagonist prevented our testing the effects of higher concentrations of antagonist; however, a higher concentration would likely have more completely blocked the effect of 8 x 10~6 M BK since the antagonist acts competitively.
7 Figure 3 shows that increasing doses of kallikrein produced a dose-dependent arteriole dilation. These results, like our previous studies, show that the dilation induced by topical application of 1 KU/ml CSF is approximately equivalent to the dilation produced by 8 X 10~6 M exogenous BK (Figure 2 ). Since previous reports of BK and kininogen levels in whole brain tissue are orders of magnitude lower than 8 x 10" 6 M,"~1 3 we hypothesize that the kininogen which is acted upon by kallikrein must be in or near the vascular BK receptors, such that kallikrein induces a local kinin concentration equivalent to that produced by 8 x 10~6 M exogenous BK. However, if this highly localized concentration were diluted by more distant tissue, as in analysis of whole brain, the BK concentration per gram of whole tissue would be much less. Figure 3 again shows that the antagonist by itself produces a 6% dilation. ANOVA of the kallikrein and kallikrein plus antagonist responses shown in Figure 3 indicated a significant difference atp < 0.0001. Analysis by Tukey's Studentized range test showed that the response to each dose of kallikrein alone was significantly different from the response to the same dose of kallikrein in the presence of the BK antagonist. Since the antagonist completely blocked the response to 0.1 and 0.3 KU/ml CSF, these results imply that the kallikrein-induced dilation at these concentrations is due solely to the formation of kinin.
Vavrek and Stewart 7 have previously reported that the BK antagonist which we employed has no effect on the rat blood pressure, rat uterus, or guinea pig ileum responses to Angiotensin II or Substance P. However, we wished to determine if the BK antagonist was a specific inhibitor in the cerebral circulation. We therefore tested the effect of the BK antagonist on the response to adenosine, acetylcholine, or VIP, 3 chemically dissimilar agonists known to produce cerebral arteriole dilation. Each agent was employed at approximately its EDso, as determined by our published and unpublished investigations in rabbits, 1 because that concentration allowed us to determine if the antagonist increased or decreased the response to each dilator. Figure 4 shows that the BK antagonist did not affect cerebral arteriole dilation in response to adenosine, acetylcholine, or VIP, providing further proof that the BK antagonist specifically blocks the action of kinins. We attempted to study the effect of the BK antagonist on Substance P activity; however, this was not completed since in 18 arterioles in 6 rabbits we found that 8 /xM Substance P induced only 9 ± 1 % arteriolar dilation.
The current results are among the first to show that the competitive kinin antagonist developed by Vavrek and Stewart 7 can block kinins generated from endogenous kininogen. These results strengthen our previous suggestion that the brain kallikrein-kinin system may play a role in modulating the cerebral circulation. In addition, our current data provide the pharmacologic foundation for future studies using the BK antagonist to explore the possible role of the kallikrein-kinin system in the brain's cerebrovascular response to several pathophysiologic phenomena. For example, Wei et al 14 and Kontos et al 15 have shown that concussive brain injury or acute hypertension injure cerebral vessels by a cyclooxygenase-dependent mechanism. We should be useful in further probing the specific role of the endogenous kallikrein-kinin system and the therapeutic potential of the BK antagonist in these pathophysiologic phenomena.
